About PhRMA
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are laser focused on developing innovative medicines that transform lives and create a healthier world. Together, we are fighting for solutions to ensure patients can access and afford medicines that prevent, treat and cure disease. Over the last decade, PhRMA member companies have invested more than $850 billion in the search for new treatments and cures, and they support nearly five million jobs in the United States.
Connect with PhRMA
For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.VotersforCures.org
www.AmericasMedicines.com
www.Facebook.com/PhRMA
www.X.com/PhRMA
The Pharmaceutical Research and Manufacturers of America (PhRMA) submitted comments in response to the proposed rule that addresses many topics of great importance both to Medicaid and to our country’s health care system generally. Several of these issues, in fact, could have a central role in shaping the future course of our health care system. Moreover, these proposals could have widespread impacts on the biopharmaceutical marketplace, as they focus on or have repercussions for several government pricing metrics (Medicaid rebate metrics and the Medicaid unit rebate amount, the 340B Program ceiling price and Medicare Part B drug payments). As a result, we are concerned that CMS packaged these issues into one proposed rule with a 30-day comment period, which denies commenters adequate time and opportunity to prepare comments on these issues.
Comment
Medicaid
PhRMA Comments on CMS Proposed Rule on Changes to Medicaid
PhRMA Comments on CMS Proposed Rule on Changes to Medicaid image